BTK and diffuse large B-cell lymphoma: While ibrutinib is a well-established BTK inhibitor that disrupts downstream NF-κB signaling, a critical oncogenic node in ABC-DLBCL, our data revealed that the enhanced cell death induced by ibrutinib and GPX4 inhibition could be fully rescued by ferrostatin-1.